LNTH

Lantheus Holdings Inc

LNTH, USA

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

https://www.lantheus.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LNTH
stock
LNTH

Lantheus Holdings Rises on Truist Upgrade with Higher Price Target StocksToTrade

Read more →
LNTH
stock
LNTH

Lantheus Stock Surges After Upgrade and Raised Price Target timothysykes.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$80.9286

Analyst Picks

Strong Buy

9

Buy

3

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

24.51

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.03

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.22 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

24.65 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.03

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 111.21% of the total shares of Lantheus Holdings Inc

1.

BlackRock Inc

(12.5502%)

since

2025/06/30

2.

HHG PLC

(10.2053%)

since

2025/06/30

3.

Vanguard Group Inc

(10.0554%)

since

2025/06/30

4.

Farallon Capital Management, L.L.C.

(9.8865%)

since

2025/06/30

5.

FMR Inc

(7.3817%)

since

2025/06/30

6.

State Street Corp

(3.763%)

since

2025/06/30

7.

iShares Core S&P Mid-Cap ETF

(3.3121%)

since

2025/08/31

8.

Vanguard Total Stock Mkt Idx Inv

(3.0506%)

since

2025/07/31

9.

Geode Capital Management, LLC

(2.6134%)

since

2025/06/30

10.

Wellington Management Company LLP

(2.5287%)

since

2025/06/30

11.

Amvescap Plc.

(2.4763%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(2.3894%)

since

2025/08/31

13.

Vanguard Small Cap Index

(2.3462%)

since

2025/07/31

14.

Westfield Capital Management Company, L.P.

(2.1988%)

since

2025/06/30

15.

T. Rowe Price Investment Management,Inc.

(2.0978%)

since

2025/06/30

16.

Reinhart Mahoney Capital Management Inc

(2.0644%)

since

2025/06/30

17.

Dimensional Fund Advisors, Inc.

(2.0342%)

since

2025/06/30

18.

Swedbank AB

(1.8071%)

since

2025/06/30

19.

Janus Inst Mid Cap Growth CF

(1.6662%)

since

2025/06/30

20.

Janus Henderson Enterprise D

(1.6662%)

since

2025/06/30

21.

Macquarie Group Ltd

(1.6507%)

since

2025/06/30

22.

Janus Henderson US Opportunistic Alpha

(1.5846%)

since

2025/06/30

23.

Janus Henderson Contrarian D

(1.5846%)

since

2025/06/30

24.

T. Rowe Price Associates, Inc.

(1.5198%)

since

2025/06/30

25.

Silvercrest Asset Management Group LLC

(1.4948%)

since

2025/06/30

26.

Janus Henderson US SMID Cap Growth

(1.4745%)

since

2025/06/30

27.

Janus Henderson US SMID Cap Growth MA

(1.4745%)

since

2025/06/30

28.

Janus Henderson Triton D

(1.4745%)

since

2025/06/30

29.

Vanguard Small Cap Growth Index Inv

(1.3213%)

since

2025/07/31

30.

JPMorgan Chase & Co

(1.3173%)

since

2025/06/30

31.

Northern Trust Corp

(1.2736%)

since

2025/06/30

32.

Charles Schwab Investment Management Inc

(1.2272%)

since

2025/06/30

33.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0941%)

since

2025/07/31

34.

Macquarie Small Cap Core I

(1.08%)

since

2025/07/31

35.

Strategic Advisers Fidelity US TtlStk

(1.0703%)

since

2025/07/31

36.

Fidelity Small Cap Index

(0.9965%)

since

2025/06/30

37.

Fidelity Value

(0.9802%)

since

2025/07/31

38.

iShares Russell 2000 Growth ETF

(0.8725%)

since

2025/08/31

39.

T. Rowe Price Integrated US SmCapGrEq

(0.8109%)

since

2025/06/30

40.

T. Rowe Price Integrated US Sm Gr Eq

(0.8109%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.26

Latest Release

Date

2025-09-30

EPS Actual

1.27

EPS Estimate

1.28

EPS Difference

-0.01

Surprise Percent

-0.7813%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.